TABLE 2.

siRNA clinical trials.

Name	Therapeutics	Delivery system	Sponsor	Phase and status
ONPATTRO (patisiran, ALN-TTR02)	TTR-mediated amyloidosis	LNP (DLin-MC3-DMA)	Alnylam Pharmaceuticals	Approved commercialized
PRO-040201	Hypercholesterolemia	LNP	Arbutus Biopharma Corporation	Phase I/II terminated
DCR-PH1	Primary hyperoxaluria type 1	LNP	Dicerna Pharmaceuticals	Phase I terminated
ARB-001467	Hepatitis B	LNP	Arbutus Biopharma Corporation	Phase II completed
TKM-100802	Ebola	LNP	Arbutus Biopharma Corporation	Phase I terminated
TKM-080301	Hepatocellular carcinoma, hepatoma, liver cancer, liver cell carcinoma, neuroendocrine tumors, and cancers with hepatic metastases	LNP	Arbutus Biopharma Corporation	Phase I/II completed
Atu027	Carcinoma and pancreatic ductal	Cationic lipoplex	Silence therapeutics	Phase I/II completed
DCR-MYC	Hepatocellular carcinoma	LNP	Dicerna Pharmaceuticals, Inc.	Phase I/II terminated and has results
ALN-VSP02	Solid tumors	LNP (Dlin-DMA)	Alnylam Pharmaceuticals	Phase I completed and program hold
siRNA-EphA2-DOPC	Advanced cancers	Liposome	M.D. Anderson Cancer Center	Phase I recruiting
ND-L02-s0201	Idiopathic pulmonary fibrosis	LNP and vitamin A	Bristol-Myers Squibb	Phase II recruiting